Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00229437|
Recruitment Status : Completed
First Posted : September 29, 2005
Last Update Posted : February 28, 2012
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Neuropathies||Drug: TAK-128 Drug: Placebo||Phase 2|
Polyneuropathy is a frequent complication of diabetes; it affects most individuals after prolonged hyperglycemia, and diabetic neuropathy is very common in the developed world. Chronic, insidious, distal sensorimotor polyneuropathy with autonomic impairment is the most typical form of diabetic neuropathy. Less common, but more florid presentations include autonomic symptoms or painful neuropathy. Although many patients have no or relatively few symptoms, the chronic polyneuropathy and autonomic dysfunction predispose to neurotrophic foot ulceration; consequently, diabetes is the leading cause of amputation today.
Diabetic neuropathy is a dying-back polyneuropathy with distal degeneration of the longest nerve fibers advancing in a centripetal direction. Multiple histopathological changes are observed, but progressive fiber loss is the hallmark of diabetic polyneuropathy. Other important features include endothelial cell basement membrane thickening, segmental demyelination and remyelination, and axonal atrophy. Similar pathological changes are observed in type 1 and type 2 diabetes. The severity of neuropathy as indicated by the stage of nerve fiber loss determines the clinical, electrophysiological, and quantitative sensory threshold features of this disorder. The functional measures of electrophysiological and quantitative sensory thresholds reflect the morphological changes and the clinical features.
Diabetic polyneuropathy is etiologically related to prolonged hyperglycemia with multiple consequences. Although strict glycemic control prevents neuropathy in type 1 patients if maintained for many years, similar interventions in those with type 2 diabetes mellitus are less successful. Type 2 patients may have neuropathy with considerable nerve fiber loss at the time of diagnosis because of unsuspected hyperglycemia in preceding years. Reversal of established neuropathy with strict glycemic control is not certain to occur, even if maintained for many years. Co-morbid disease often interferes with strict management of type 2 diabetes. Even among those with type 1 diabetes, a minority of patients are successful in maintaining prolonged euglycemia.
TAK-128 is a novel synthetic compound being developed as a treatment for diabetic neuropathy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||343 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy|
|Study Start Date :||March 2005|
|Actual Primary Completion Date :||May 2006|
|Actual Study Completion Date :||May 2006|
|Experimental: TAK-128 5 mg QD||
TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
|Experimental: TAK-128 50 mg QD||
TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
|Experimental: TAK-128 100 mg QD||
TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
|Placebo Comparator: Placebo QD||
TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
- Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies). [ Time Frame: Week 24 or Final Visit ]
- Change from Baseline in the electrophysiologic parameters for individual nerves, including amplitudes (Nerve Conduction Studies). [ Time Frame: Week 24 or Final Visit ]
- Change from Baseline in vibration perception threshold measurements (Quantitative Sensory Testing). [ Time Frame: Weeks 12, 24 or Final Visit ]
- Change from Baseline in pain scores (Short-Form McGill Pain Questionnaire). [ Time Frame: Weeks: 8, 12, 16, 20, 24 or Final Visit ]
- Change from Baseline in the neurological examination (Clinical Neurological Examination). [ Time Frame: Weeks 12, 24 or Final Visit ]
- Change from Baseline in quality of life index (SF-36 Health Survey). [ Time Frame: Weeks: 8, 12, 16, 20, 24 or Final Visit ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00229437
Show 48 Study Locations
|Study Director:||Medical Director||Takeda|